HomeAI · summaries
Storia in 4 fonti
ASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win
With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. | In its 2,000-patient Proteus study, J&J tested Erleada's benefits when given to certain patients with prostate cancer before and after surgery.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three years after a phase 3 flop led Takeda to withdraw…
- ·
ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win
Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. | After winning a broader FDA label in metastatic castration-resistant…
- ·
ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker
UNDER EMBARGO: Sunday May 31 7AM CST/ 8AM EST | In Lilly's Libretto-432 ASCO readout, Retevmo showed an 83% reduction in disease progression or death when used as an adjuvant…
- ·
ASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win
With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. | In its 2,000-patient Proteus study,…
- ·
morningstar.com
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of…
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long…
- ·
ASCO: Sac-TMT’s massive phase 3 program has a jarring gap. Does Merck plan to close it?
Merck & Co.’s extensive clinical development scheme for its TROP2 antibody-drug conjugate (ADC) sac-TMT already
- ·
independent.co.uk
Prostate cancer breakthrough as drug combo gives patients a powerful new chance
Data from a late-stage trial, presented on Sunday, indicate that the treatment, administered six months before and after surgery, substantially increased the chances of…
- ·
endpoints.news
J&J's Erleada study succeeds in early-stage prostate cancer, but questions remain
As part of a hormone therapy regimen for prostate cancer, J&J’s Erleada cut the risk of metastasis or death by 20% when given around surgery, researchers reported Sunday.